A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

Recruiting

Phase 1

Phase 2

AZD6489A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

Sponsor:

AstraZeneca

Code:

NCT07717840

Conditions

RSV Respiratory Syncytial Virus

Eligibility Criteria

Sex: All

Age: 60+

Healthy Volunteers: Accepted

Interventions

AZD6489

Licensed RSV vaccine #1

Licensed RSV vaccine #2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-07. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-07-21.